Nexentis subsidiary MitoCareX completes initial AI drug screening with Boltz
NXTS•Nexentis Technologies’ wholly owned subsidiary MitoCareX Bio completed initial AI-powered computational screening in a drug-discovery initiative with Boltz launched in June 2026; predictions require further analysis and experimental validation.
1. Screening results remain preliminary
MitoCareX Bio completed initial AI-powered computational screening with Boltz in its drug-discovery initiative, launched in June 2026. The preliminary predictions require further computational analysis and experimental validation before any program can advance, and MitoCareX retains control over its discovery programs and any small-molecule candidates advanced through the initiative.
